Clinical trial
A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli
NCT05488340 is registered in ClinicalTrials.gov with Locus Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli
- Lead sponsor
- Locus Biosciences
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 13, 2022
- Completion date
- December 31, 2027
- Enrollment
- 318 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.